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Jack R. Bennink, 1 Jonathan W. Yewdell 1 § "Cross-priming" describes the activation of naïve CD8 ϩ T cells by professional antigen-presenting cells that have acquired viral or tumor antigens from "donor" cells. Antigen transfer is believed to be mediated by donor cell-derived molecular chaperones bearing short peptide ligands generated by proteasome degradation of protein antigens. We show here that crosspriming is based on the transfer of proteasome substrates rather than peptides. These findings are potentially important for the rational design of vaccines that elicit CD8 ϩ T cell responses.
CD8
ϩ T cells play important roles in the elimination of pathogens, tumors, and transplanted tissues (1) . Virus-specific CD8 ϩ T cells recognize major histocompatibility complex (MHC) class I molecules bound to 8-to 10-residue peptides derived from viral proteins (2) . Induction of primary CD8 ϩ T cell responses requires that viral peptides are presented by class I molecules on "professional" antigen-presenting cells (pAPCs), particularly dendritic cells (3) , because only these cells can provide costimulatory signals required to induce the proliferation of naïve T cells. Peptides can be generated from viral proteins synthesized by infected pAPCs themselves ("direct priming") or from proteins originally synthesized by other infected "donor" cells ("cross-priming") (4) . Although direct priming is now relatively well understood, less is known about the mechanisms involved in cross-priming.
The principal hypothesis for crosspriming posits that molecular chaperones ferry peptides from donor cells to pAPCs (5) . Although there is compelling evidence for the potent in vitro antigenicity of peptides bound to molecular chaperones (6) , the participation of peptide-chaperone complexes in cross-priming in vivo has not been rigorously examined. One important prediction of the "chaperoned-peptide" hypothesis would be that the potency of donor cells in crosspriming should be directly proportional to the levels of peptides they express.
To study cross-priming, it is necessary to use donor cells that either do not express the same class I molecules as the responding mouse or cannot generate class I molecules owing to some defect in class I biosynthesis (7 ) . In the first set of experiments, we used donor cells that cannot produce class I molecules due to a targeted deletion in the gene encoding the ␤ 2 -microglobulin (␤ 2 m) subunit of class I molecules (8) . Cells that were ␤ 2 m-negative (␤ 2 m neg ) were exposed to lactacystin, an irreversible proteasome inhibitor (9) (fig. S1), and then infected for 4 hours with a recombinant vaccinia virus (rVV) expressing chicken ovalbumin (Fig. 1) . Infected cells were introduced into B6 (H-2 b ) mice that had previously received transgenic CD8 ϩ T cells from OT-I mice specific for K b class I molecules presenting a peptide consisting of ovalbumin residues 257 to 264 (Ova 257-264 ) (10) . Eighteen hours after immunization, OT-I activation was measured by increased cell surface expression of CD69. Rather than interfering with crosspriming, as predicted by the chaperonedpeptide hypothesis, lactacystin actually had an enhancing effect ( Fig. 2A) .
The effect of proteasome inhibition on cross-priming was next examined by immunization of B6 mice with ␤ 2 m neg cells infected with influenza A virus (IAV). We measured CD8
ϩ T cell responses 6 days after immunization using tetrameric D b molecules complexed to an immunogenic peptide (residues 366 to 374) from IAV nucleoprotein (NP) (Fig. 1) . To prevent infection of mice with IAV released from infected cells, we coinjected mice with a monoclonal antibody ("␣-HA") that neutralizes IAV infectivity and thereby abrogates induction of CD8 ϩ T cells by infectious IAV (Fig. 2B) . Once again, lactacystin failed to inhibit the immunogenicity of IAV-infected cells (Fig. 2C) .
Because these experiments revealed that cross-priming in these systems could occur in the absence of proteasomal degradation of protein antigens, we tested whether preprocessed peptides could also crossprime. Synthetic Ova 257-264 peptide was loaded onto splenocytes derived from mice carrying the bm1 mutation of K b (10) . Although Ova 257-264 binds to K bm1 with relatively high affinity (Fig. 3A) , these complexes fail to activate OT-I cells because of alterations in the region of K bm1 that interacts with the T cell antigen receptor (10) . We injected splenocytes pulsed with synthetic peptides into B6 mice and subsequently measured the proliferation of adoptively transferred OT-I cells. Whereas splenocytes from wild-type mice exposed to as little as 10 -9 M peptide induced OT-I proliferation, K bm1 splenocytes failed to elicit measurable OT-I responses, even when exposed to 10 -5 M peptide (Fig. 3B ). Note that, under the conditions used for pulsing cells with peptide, synthetic Ova 257-264 would have free access to the endoplasmic reticulum (ER) via a vesicular transport route (11) , where it can potentially associate with gp96 and other molecular chaperones putatively involved in crosspriming. However, the inability of peptidepulsed K bm1 cells to activate CD8 ϩ T cells indicates that neither class I molecules nor ER chaperones were capable of mediating cross-priming of exogenous peptide antigens in these experimental conditions.
We explored a more physiologically relevant system for studying peptide-based cross-priming by using donor cells in which peptides were generated by infection with rVVs expressing cytosolic (Ova 257-264 ) or ER-targeted Ova 257-264 (ER-Ova 257-264 ) minigene products or a chimeric protein labeled with green fluorescent protein (NP-S-GFP) as a positive control (Fig. 1) . After their introduction into B6 mice, each of these viruses induced measurable Ova 257-264 -specific CD8 ϩ T cell responses as determined by interferon-␥ (IFN-␥) expression (Fig. 3C) . In marked contrast, immunization of B6 mice with MHCmismatched P815 cells (H-2 d ) infected with either of the minigenes expressing rVVs failed to induce detectable Ova 257-264 -specific CD8
ϩ T cells (Fig. 3D ). Cross- (Fig. 3D) .
In all experiments using rVV-infected cells, ultraviolet (UV) irradiation was used just before injection to prevent possible transfer of infectious virus. However, because UV irradiation inhibits protein synthesis ( fig. S1 ) and minigene products are rapidly degraded within the cells (12) , it remained possible that cells actively synthesizing minigene products could function in cross-priming. We eliminated this possibility by using a human cell line that produced cytosolic Ova 257-264 from a transfected plasmid. These cells failed to induce a CD8 ϩ T cell response, whereas control cells transfected with a plasmid expressing a metabolically stable chimeric protein (GFP-S) (Fig. 1) were immunogenic (Fig. 3E) .
These experiments indicated that cells expressing stable proteins were capable of cross-priming, whereas those expressing minimal peptides were not. Minimal peptides (8 to 11 amino acids) are not, however, typically generated by proteasomes, which predominantly generate longer peptides (13, 14) . To investigate the immunogenicity of cells producing natural proteasome products from a full-length protein, we infected P815 cells with a rVV chimeric protein designed to be rapidly degraded (R-NP-S-GFP) (Fig. 1) . This virus is highly immunogenic when used to infect mice (Fig. 4A) ; however, cells expressing R-NP-S-GFP were unable to crossprime unless they were first treated with lactacystin to prevent its degradation (Fig. 3B) . This clearly demonstrates that natural proteasome products were not able to cross-prime in this system.
Our findings, in conjunction with those of others (15, 16 ), demonstrate that crosspriming in vivo is based on the transfer of proteins, rather than peptides, as postulated by the chaperoned-peptide cross-priming hypothesis (5) . This also extends a prior demonstration that cross-priming does not require transport of peptides into the ER by the transporter associated with antigen processing (17 ) . Although these findings do not eliminate the possible participation of molecular chaperones in cross-priming, they do indicate that a putative chaperone ligand needs to achieve a sufficiently high steady-state level within cells. We further suggest that a role for chaperones in ferrying antigens to specific receptors on pAPCs might be superfluous in circumstances in which antigens are acquired through the process of phagocytosis of debris from dead or dying cells (18, 19) . Consistent with this idea, a number of studies indicate that simply aggregating protein antigens (in the absence of molecular chaperones) greatly enhances their immunogenicity [reviewed in (20) ].
It is important to recognize that our conclusions are strictly based on in vivo studies and do not address mechanisms of cross-presentation that occur in vitro, where solid evidence has been presented recently for the activities of proteasomegenerated peptide products (21) and peptide-loaded chaperones (6 ) . Further, our findings do not preclude therapeutic applications of molecular chaperones for inducing CD8 ϩ T cells (5). Our study does, however, suggest a potentially important design principle for gene-based vaccines. Thus, vaccine antigens presented via direct priming should be engineered to maximally generate class I binding peptides (22) , whereas vaccine antigens presented via cross-priming should be engineered for maximum metabolic stability. There are 481 segments longer than 200 base pairs (bp) that are absolutely conserved (100% identity with no insertions or deletions) between orthologous regions of the human, rat, and mouse genomes. Nearly all of these segments are also conserved in the chicken and dog genomes, with an average of 95 and 99% identity, respectively. Many are also significantly conserved in fish. These ultraconserved elements of the human genome are most often located either overlapping exons in genes involved in RNA processing or in introns or nearby genes involved in the regulation of transcription and development. Along with more than 5000 sequences of over 100 bp that are absolutely conserved among the three sequenced mammals, these represent a class of genetic elements whose functions and evolutionary origins are yet to be determined, but which are more highly conserved between these species than are proteins and appear to be essential for the ontogeny of mammals and other vertebrates.
Although only about 1.2% of the human genome appears to code for proteins (1) (2) (3) , it has been estimated that as much as 5% is more conserved than would be expected from neutral evolution since the split with rodents, and hence may be under negative or "purifying" selection (4-6). Several studies have found specific noncoding segments in the human genome that appear to be under selection, using a threshold for conservation of 70 or 80% identity with the mouse over more than 100 base pairs (bp) (7) (8) (9) (10) (11) (12) (13) . A study of these elements on human chromosome 21 found that those that were very highly conserved in multiple species contained significant numbers of noncoding elements (13) . Similar results were found when comparing the human, mouse, and rat genomes (14, 15) in a study of the 1.8 -megabase (Mb) CFTR region (16, 17) and in a functional study of the SIM2 locus in a number of mammalian species (18) . We determined the longest segments of the human genome that are maximally conserved with orthologous segments in rodents: those showing 100% identity and with no insertions or deletions in their alignment with the mouse and rat. Exclusive of ribosomal RNA (rRNA) regions, there are 481 such segments longer than 200 bp that we call ultraconserved elements (table S1). They are widely distributed in the genome (on all chromosomes except chromosomes 21 and Y) and are often found in clusters (Fig. 1) . The probability is less than 10 Ϫ22 of finding even one such element in 2.9 billion bases under a simple model of neutral evolution with independent substitutions at each site, using the slowest neutral substitution rate that is observed for any 1-Mb region of the genome (supporting text, section S1). Nearly all of these elements also exhibit extremely high levels of conservation with orthologous regions in the chicken genome [467 out of 481 (467/481) ϭ 97% of the elements aligning at an average of 95.7% identity, 29 at 100% identity] and about two-thirds of them with the fugu genome as well (324/481 ϭ 67.3% of the elements aligning at an average of 76.8% identity), despite the fact that only about 4% of the human genome can be reliably aligned to the chicken genome (at an average of 62.9% identity where an alignment is found), and less than 1.8% of the human genome aligns to fugu (at an average of 60% identity). In addition, nearly all exhibit extremely high levels of conservation with the dog genome, which was estimated using reads from the National Center for Biotechnology Information (NCBI) trace archive (477/481 ϭ 99.2% of the elements aligning at an average of 99.2% identity).Thus, it appears that nearly all of these ultraconserved elements may have been under extreme negative selection in many species for more than 300 million years, and some of them for at least 400 million years.
As expected, the ultraconserved elements exhibit almost no natural variation in the human population. Only 6 out of 106,767 bases examined in the ultraconserved elements (excluding the first and last 20 bases in each element) are at validated singlenucleotide polymorphisms (SNPs) in NCBI's SNP database (dbSNP) (table S2a). For this much DNA, we would have expected 119 validated sites, so validated SNPs are underrepresented by 20-fold (P Ͻ 10 Ϫ42 ). The 48 unvalidated SNPs we found revealed many likely errors in the unvalidated portion of dbSNP (table S2b) . These same 106,767 bases exhibit very few differences with the chimp genome as well, showing only 38 single base changes where the chimp base has a Phred quality score at least 45, whereas the expected number would be 716 (roughly a 19-fold reduction, P Ͻ 10 Ϫ200 ; supporting text, section S2). This low level of variation within the human population and in comparison with the chimp suggests that these elements are currently changing at a rate that is roughly 20 times slower than the average for the genome. Only 4.3% of the bases are different in the chicken, which is also consistent with a roughly 20-fold reduction from neutral substitution rates (supporting text, section S2).
Of the 481 ultraconserved elements, 111 overlap the mRNA of a known human protein-coding gene [including the untranslated regions (UTRs)], 256 show no evidence of transcription from any matching expressed sequence tag (EST) or mRNA from any species, and for the remaining 114 the evidence for transcription is inconclusive. We call these partly exonic (or exonic for short), nonexonic, and possibly exonic ultraconserved elements, respectively. A hundred nonexonic elements are located in introns of known genes and the rest are intergenic. The non-exonic elements, both intronic and intergenic, tend to congregate in clusters near transcription factors and developmental genes, whereas the exonic and possibly
